Literature DB >> 12667125

Lobectomy by video-assisted thoracic surgery for lung cancer patients aged 80 years or more.

Kiyoshi Koizumi1, Shuji Haraguchi, Tomomi Hirata, Kyoji Hirai, Iwao Mikami, Mitsuhiro Fukushima, Daisuke Okada, Shigeki Yamagishi, Yutaka Enomoto, Keisuke Nakayama, Hirohiko Akiyama, Shigeo Tanaka.   

Abstract

To clarify the usefulness of video-assisted lobectomy for lung cancer patient aged 80 years old or more, a retrospective study was conducted to evaluate the clinical outcome. Between 1982 and 2001, 914 patients underwent surgery for primary lung cancer at the Nippon Medical School Hospital. Among them, 32 patients underwent lobectomy, including 17 with a mean age of 82 years (range, 80 to 91 years) who underwent video-assisted lobectomy and 15 with a mean age of 82 years (range, 80 to 86 years) who underwent lobectomy by standard thoracotomy. Of these 32 patients, clinical outcome was evaluated retrospectively. Mortality was 4 (12.5%) of 32 patients consisting of 3 (20%) of 15 who underwent lobectomy by standard thoracotomy and 1 (5.9%) of 17 who underwent video-assisted lobectomy. Single variate analyses revealed that the presence of preoperative cardiopulmonary disease, 0.6 L or more of predicted postoperative forced expiratory volume in one second/m(2), 700 ml or more of blood loss, five hours or more of duration of operation and two or more of postoperative complications were considered as risk factors regarding mortality within three months postoperation. Among the patients who underwent lobectomy with mediastinal lymph node dissection, the 5-year survival rate at stage I (IA+IB) was 55.6% for patients who underwent video-assisted lobectomy and 0% for patients who underwent lobectomy by standard thoracotomy (IA=2, IB=2). Video-assisted lobectomy for lung cancer patients aged 80 years or more is considered to offer an acceptable clinical outcome. However, further observation on prognosis is necessary.

Entities:  

Mesh:

Year:  2003        PMID: 12667125

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  8 in total

Review 1.  Surgical treatment of non-small-cell lung cancer in octogenarians.

Authors:  Miguel Guerra; Paulo Neves; José Miranda
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-02-08

2.  Results of Lung Cancer Surgery for Octogenarians.

Authors:  Haruaki Hino; Tomohiro Murakawa; Junji Ichinose; Kazuhiro Nagayama; Junichi Nitadori; Masaki Anraku; Jun Nakajima
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-03-16       Impact factor: 1.520

3.  Risk factors for postoperative complications after lung resection for non-small cell lung cancer in elderly patients at a single institution in China.

Authors:  Guotian Pei; Shijie Zhou; Yi Han; Zhidong Liu; Shaofa Xu
Journal:  J Thorac Dis       Date:  2014-09       Impact factor: 2.895

4.  Emergency thoracic surgery in elderly patients.

Authors:  Stefan Limmer; Lena Unger; Ralf Czymek; Peter Kujath; Martin Hoffmann
Journal:  JRSM Short Rep       Date:  2011-02-18

Review 5.  Video-assisted thoracic surgery (VATS) lobectomy: the evidence base.

Authors:  Naveed Alam; Raja M Flores
Journal:  JSLS       Date:  2007 Jul-Sep       Impact factor: 2.172

6.  Stereotactic ablative body radiation therapy for tumors in the lung in octogenarians: a retrospective single institution study.

Authors:  Nathan A Cannon; Puneeth Iyengar; Hak Choy; Robert Timmerman; Jeffrey Meyer
Journal:  BMC Cancer       Date:  2014-12-17       Impact factor: 4.430

7.  Safety and efficacy of thoracoscopic wedge resection for elderly high-risk patients with stage I peripheral non-small-cell lung cancer.

Authors:  Ling Lin; Dingzhong Hu; Chenxi Zhong; Heng Zhao
Journal:  J Cardiothorac Surg       Date:  2013-12-21       Impact factor: 1.637

8.  Lobectomy in octogenarians: real world outcomes for robotic-assisted, video-assisted thoracoscopic, and open approaches.

Authors:  Inderpal S Sarkaria; Madhu Lalitha Gorrepati; Shilpa Mehendale; Daniel S Oh
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.